Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.80 |
| ▸ | TTR | P02766 | 1/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | HPGD | P15428 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | CASP1 | P29466 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 3/20 | 0.66 |
| ▸ | THRB | P10828 | 2/20 | 0.62 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | CASP7 | P55210 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1718621 | 0.90 | HSD17B10 (0.69) | KDM4EALDH1A1HSD17B10TTRSMN1; SMN2 | |
| SCHEMBL3284626 | 0.89 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10TTRSMN1; SMN2 | |
| SCHEMBL3278525 | 0.89 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10TTRSMN1; SMN2 | |
| SCHEMBL1718676 | 0.88 | TTR (1.00) | KDM4EALDH1A1HSD17B10TTRSMN1; SMN2 | |
| SCHEMBL1719145 | 0.88 | KDM4E (0.80) | KDM4EALDH1A1HSD17B10TTRSMN1; SMN2 | |
| SCHEMBL6030712 | 0.88 | KDM4E (0.80) | KDM4EALDH1A1HSD17B10TTRSMN1; SMN2 | |
| SCHEMBL14014278 | 0.85 | ALDH1A1 (0.64) | KDM4EALDH1A1HSD17B10TTRSMN1; SMN2 | |
| SCHEMBL1718174 | 0.85 | ALDH1A1 (0.83) | KDM4EALDH1A1HSD17B10TTRSMN1; SMN2 | |
| SCHEMBL16614838 | 0.83 | HPGD (0.81) | KDM4EALDH1A1HSD17B10SMN1; SMN2HPGD | |
| SCHEMBL16615188 | 0.83 | HPGD (0.81) | KDM4EALDH1A1HSD17B10SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264412-A1 | Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | claimed |
| US-20090137574-A1 | Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and Disorders | NOVO NORDISK A/S (DK) | 2009-05-28 | — | — | US | claimed |
| US-20070270408-A1 | Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines | NOVO NORDISK A/S (DK) | 2007-11-22 | — | — | US | claimed |
| EP-1782859-A2 | Pharmaceutical use of substituted pyrazolo [1,5- a]pyrimidines | NOVO NORDISK A/S (DK) | 2007-05-09 | — | — | EP | claimed |
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | NOVO NORDISK A/S (DK) | 2006-05-25 | — | — | US | claimed |
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HIGH POINT PHARMACEUTICALS, LLC | 2006-05-04 | — | — | US | claimed |
| EP-1615667-A2 | COMBINATIONS OF AN 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| EP-1615666-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| EP-1615697-A2 | NEW PYRAZOLO[1,5-A] PYRIMIDINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| WO-2004089416-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089471-A2 | NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089415-A2 | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| US-9221840-B2 | Treating protein folding disorders with small molecule CFTR correctors | DISCOVERYBIOMED INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221840-B2 | Treating protein folding disorders with small molecule CFTR correctors | DISCOVERYBIOMED INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140073632-A1 | TREATING PROTEIN FOLDING DISORDERS WITH SMALL MOLECULE CFTR CORRECTORS | THE UAB RESEARCH FOUNDATION (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073632-A1 | TREATING PROTEIN FOLDING DISORDERS WITH SMALL MOLECULE CFTR CORRECTORS | THE UAB RESEARCH FOUNDATION (US) | 2014-03-13 | — | — | US | disclosed |
| WO-2004089416-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089415-A2 | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| US-20030176450-A1 | Pyrazolopyrimidines | ICAGEN, INC. (US) | 2003-09-18 | — | — | US | disclosed |
| WO-2003037900-A2 | PYRAZOLOPYRIMIDINES | ICAGEN, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270408-A1 | Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines | HSD3B1, HSD11B1, SRD5A1 | KDM4E 3872/4885ALDH1A1 133/4885HSD17B10 44/4885 |
| US-20140073632-A1 | TREATING PROTEIN FOLDING DISORDERS WITH SMALL MOLECULE CFTR CORRECTORS | CFTR, CLCN2, SLC47A1 | KDM4E 4485/4885ALDH1A1 3785/4885HSD17B10 1430/4885 |
| US-20030176450-A1 | Pyrazolopyrimidines | SCN3A, TRPV3, P2RX3 | KDM4E 2962/4885ALDH1A1 2830/4885HSD17B10 3989/4885 |
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HSD11B1, HSD17B1, NR3C1 | KDM4E 4690/4885ALDH1A1 253/4885HSD17B10 29/4885 |
| US-20090137574-A1 | Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and Disorders | HSD11B1, HSD11B2, HSD17B1 | KDM4E 4283/4885ALDH1A1 74/4885HSD17B10 16/4885 |
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | HSD11B1, HSD11B2, HSD17B1 | KDM4E 4283/4885ALDH1A1 74/4885HSD17B10 16/4885 |
| US-20090264412-A1 | Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy | HSD11B1, HSD17B1, NR3C1 | KDM4E 4690/4885ALDH1A1 253/4885HSD17B10 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.